A phase I dose-finding and pharmacokinetic study of RTA 401 (CDDO) administered as a day continuous intravenous infusion in patients with relapsed or refractory leukemias or high-risk myelodysplastic syndromes

Trial Profile

A phase I dose-finding and pharmacokinetic study of RTA 401 (CDDO) administered as a day continuous intravenous infusion in patients with relapsed or refractory leukemias or high-risk myelodysplastic syndromes

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Dec 2005

At a glance

  • Drugs Bardoxolone (Primary)
  • Indications Leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top